Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Early TNBC
NCT06358573Phase 2Recruiting
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of INT230-6 in triple-negative breast cancer (TNBC), sponsored by Swiss Group for Clinical Cancer Research. Started Oct 2024; status: recruiting.
02
Drugs
INT230-6
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06358573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358573.